Pharmacotherapeutic determinants for QTc interval prolongation in japanese patients with mood disorder

Pharmacopsychiatry

Volumn 45, Issue 7, 2012, Pages 279-283

  Okayasu, H ^a   Ozeki, Y ^a,b   Fujii, K ^a   Takano, Y ^a   Saeki, Y ^a   Hori, H ^b   Horie, M ^c   Higuchi, T ^d   Kunugi, H ^b   Shimoda, K ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF NEUROSCIENCE   (Japan)

^c SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^d NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

Author keywords

antidepressants; QTc interval; selective serotonine reuptake inhibitors; sudden death; tricyclic antidepressants

Indexed keywords

AMITRIPTYLINE; AMOXAPINE; ANTIDEPRESSANT AGENT; BIPERIDEN; CARBAMAZEPINE; CHLORPROMAZINE; CLOMIPRAMINE; DIAZEPAM; FLUVOXAMINE; IMIPRAMINE; LITHIUM; MAPROTILINE; MIANSERIN; MILNACIPRAN; NORTRIPTYLINE; PAROXETINE; SERTRALINE; TRAZODONE; VALPROIC ACID;

ADULT; AGE; ARTICLE; BIPOLAR DISORDER; FEMALE; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MOOD DISORDER; PRIORITY JOURNAL; QT PROLONGATION; QTC INTERVAL PROLONGATION; SEX DIFFERENCE;

AGE FACTORS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; ANTIPSYCHOTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; LONG QT SYNDROME; MALE; MIDDLE AGED; MOOD DISORDERS; REGRESSION ANALYSIS; SEROTONIN UPTAKE INHIBITORS; SEX CHARACTERISTICS;

EID: 84869498857     PISSN: 01763679     EISSN: 14390795     Source Type: Journal    
DOI: 10.1055/s-0032-1308969     Document Type: Article

References (25)

1. Sicouri S., Antzelevitch C. Sudden cardiac death secondary to antidepressant and antipsychotic drugs. Expert Opin Drug Saf: 2008; 7 181 194
2. Straus S. M., Kors J. A., De Bruin M. L. et al. Prolonged QTc interval and risk of sudden cardiac death in a population of older adults. J Am Coll Cardiol: 2006; 47 362 367
3. Reilly J. G., Ayis S. A., Ferrier I. N. et al. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet: 2000; 355 1048 1052
4. Vieweg W. V., Wood M. A., Fernandez A. et al. Proarrhythmic risk with antipsychotic and antidepressant drugs: implications in the elderly. Drugs Aging: 2009; 26 997 1012
5. Whang W., Kubzansky L. D., Kawachi I. et al. Depression and risk of sudden cardiac death and coronary heart disease in women: results from the Nurses' Health Study. J Am Coll Cardiol: 2009; 53 950 958
6. International Registry for Drug-induced Arrhythmias Arizona classification lists January 5: 2012; Available at http://www.azcert.org/ medical-pros/drug-lists/bycategory.cfm#
7. Bazett H. C. The time relations of the blood-pressure changes after excision of the adrenal glands, with some observations on blood volume changes. J Physiol: 1920; 53 320 339
8. Inada I. Dose equivalence of psychotropic drugs: 2006-version. Jpn J Clin Psychopharmacol: 2006; 9 1443 1447
9. Chan A., Isbister G. K., Kirkpatrick C. M. et al. Drug-induced QT prolongation and torsades de pointes: evaluation of a QT nomogram. QJM: 2007; 100 609 615
10. The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) E14, The clinical evaluation of qt/qtc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs January 5: 2012; Available at http://www.ich.org/ products/guidelines/efficacy/efficacy-single/article/the-clinical-evaluation-of- qtqtc-interval-prolongation-and-proarrhythmic-potential-for-non-antiarrh.html
11. Blaschke D., Parwani A. S., Huemer M. et al. Torsade de pointes during combined treatment with risperidone and citalopram. Pharmacopsychiatry: 2007; 40 294 295
12. van Noord CS S., Sturkenboom M. C., Hofman A. et al. Psychotropic drugs associated with corrected QT interval prolongation. J Clin Psychopharmacol: 2009; 29 9 15
13. Hamer M., David Batty G., Seldenrijk A. et al. Antidepressant medication use and future risk of cardiovascular disease: the Scottish Health Survey. Eur Heart J: 2011; 32 437 442
14. Ray W. A., Meredith S., Thapa P. B. et al. Cyclic antidepressants and the risk of sudden cardiac death. Clin Pharmacol Ther: 2004; 75 234 241
15. Tie H., Walker B. D., Valenzuela S. M. et al. The heart of psychotropic drug therapy. Lancet: 2000; 355 1825
16. Staudacher I., Wang L., Wan X. et al. hERG K(+) channel-associated cardiac effects of the antidepressant drug desipramine. Naunyn Schmiedebergs Arch Pharmacol: 2011; 383 119 139
17. + current inhibition, disruption of protein trafficking, and apoptosis induced by amoxapine. Naunyn Schmiedebergs Arch Pharmacol: 2010; 381 385 400
18. Jo S. H., Hong H. K., Chong S. H. et al. Clomipramine block of the hERG K+ channel: accessibility to F656 and Y652. Eur J Pharmacol: 2008; 592 19 25
19. Jo S. H., Youm J. B., Lee C. O. et al. Blockade of the HERG human cardiac K(+) channel by the antidepressant drug amitriptyline. Br J Pharmacol: 2000; 129 1474 1480
20. Witchel H. J., Pabbathi V. K., Hofmann G. et al. Inhibitory actions of the selective serotonin re-uptake inhibitor citalopram on HERG and ventricular L-type calcium currents. FEBS Lett: 2002; 512 59 66
21. Thomas D., Gut B., Wendt-Nordahl G. et al. The antidepressant drug fluoxetine is an inhibitor of human ether-a-go-go-related gene (HERG) potassium channels. J Pharmacol Exp Ther: 2002; 300 543 548
22. Milnes J. T., Crociani O., Arcangeli A. et al. Blockade of HERG potassium currents by fluvoxamine: incomplete attenuation by S6 mutations at F656 or Y652. Br J Pharmacol: 2003; 139 887 898
23. Ozeki Y., Fujii K., Kurimoto N. et al. QTc prolongation and antipsychotic medications in a sample of 1017 patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry: 2010; 34 401 405
24. U.S. Food and Drug administration FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide) on August 24, 2011, January 5, 2012 Available at http://www.fda.gov/Drugs/ DrugSafety/ucm269086.htm
25. Wenzel-Seifert K., Wittmann M., Haen E. Torsade de Pointes episodes under treatment with selective serotonin reuptake inhibitors. Pharmacopsychiatry: 2010; 43 279 281